Get the Stockscreener App
0.9931
0.53%
-0.0053
Oncolytics Biotech Inc stock is traded at $0.9931, with a volume of 481.06K.
It is down -0.53% in the last 24 hours and down -12.50% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.9984
Open:
$0.9712
24h Volume:
481.06K
Relative Volume:
0.55
Market Cap:
$106.86M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.7546
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
+0.10%
1M Performance:
-12.50%
6M Performance:
+72.14%
1Y Performance:
+18.83%
1-Day Range:
$0.9712
$1.04
1-Week Range:
$0.9401
$1.04
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9931 | 107.43M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion - The Globe and Mail
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - PR Newswire
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Oncolytics Biotech Plans Jurisdiction Shift to Nevada - The Globe and Mail
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech reschedules shareholder vote on U.S. domicile move By Investing.com - Investing.com Nigeria
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporat - pharmiweb.com
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada - The AI Journal
Oncolytics Biotech Reschedules Special Meeting Of Shareholders To Change Jurisdiction Of Incorporation To Nevada - TradingView — Track All Markets
Published on: 2025-12-08 13:44:04 - moha.gov.vn
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality - The Manila Times
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality - GlobeNewswire Inc.
Oncolytics to test immunotherapy against aggressive pancreatic cancer - Rare Cancer News
Is Oncolytics Biotech Inc. stock dividend yield sustainableMarket Volume Summary & Low Risk Profit Maximizing Plans - Newser
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - sharewise.com
Is Oncolytics Biotech Inc. stock undervalued vs historical averages2025 Historical Comparison & Weekly Watchlist for Hot Stocks - Newser
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality - The Globe and Mail
ONCY: Virtual Meeting Scheduled for December 8 - GuruFocus
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Oncolytics Biotech Inc. stock a buy for dividend growthJuly 2025 Trade Ideas & Safe Swing Trade Setups - moha.gov.vn
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential (PR Newswire) - Aktiellt
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep - Aktiellt
Oncolytics Biotech Reports Q3 2025 Financial Results - TipRanks
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types (PR Newswire) - Aktiellt
This Canadian biotech stock is tackling pancreatic Cancer - Cantech Letter
Are Analysts Too Optimistic About Nagreeka Capital Infrastructure Ltds Revenue GrowthGap Up/Gap Down Analysis & Achieve Consistent Profits - earlytimes.in
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital - The Globe and Mail
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy - MSN
Can Oncolytics Biotech Inc. stock sustain free cash flow growthJuly 2025 Sector Moves & Real-Time Volume Surge Alerts - newser.com
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders - BioSpace
Can Oncolytics Biotech Inc. stock attract ESG capital inflowsJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Oncolytics Biotech Reschedules Shareholder Meeting Amid SEC Delays - The Globe and Mail
Identifying reversal signals in Oncolytics Biotech Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - newser.com
Oncolytics Biotech reschedules special meeting due to government shutdown By Investing.com - Investing.com Nigeria
Oncolytics Biotech reschedules special meeting due to government shutdown - Investing.com India
Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 By Investing.com - Investing.com Australia
FY2025 EPS Estimate for Oncolytics Biotech Lifted by Analyst - MarketBeat
Oncolytics Biotech (TSX:ONC) Growth In Emerging Global Oncology Markets - Kalkine Media
Oncolytics Biotech (TSE:ONC) Advances Clinical Focus in Cancer Therapy - Kalkine Media
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - BioSpace
Can Oncolytics Biotech Inc. stock rebound after recent weaknessDollar Strength & Long-Term Growth Portfolio Plans - newser.com
What recovery options are there for Oncolytics Biotech Inc.Quarterly Trade Report & Expert Approved Momentum Ideas - newser.com
Will Oncolytics Biotech Inc. outperform the marketWeekly Stock Summary & Community Consensus Stock Picks - newser.com
Using data tools to time your Oncolytics Biotech Inc. exitTreasury Yields & Low Drawdown Trading Techniques - newser.com
Backtesting results for Oncolytics Biotech Inc. trading strategies2025 Technical Patterns & Precise Buy Zone Identification - newser.com
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech (ONCY) Advances with FDA-Approved Study Desig - GuruFocus
Oncolytics Biotech Reaches FDA Alignment on Phase 3 Pancreatic Cancer Trial Design - marketscreener.com
Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 - Investing.com India
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):